The International Exchange of Professionals - Thematic Event in Pharmaceutical Science and Technology & The 20th Annual Congress of International Drug Discovery Science & Technology 2024 (Europe) was successfully held on June 17-19, 2024 at Radisson Blu Beke Hotel, Budapest, Hungary. It was proudly hosted by Word High Technology Society, supported by China Association for international Exchange of Personnel and Budapest Convention Bureau, and efficiently operated by BIT Group Global Ltd. and Shenzhen Center for International Exchange of Personnel. Following the meticulous preparation, we
are pleased to welcome over 110 specialists from 25 countries and areas joining us in this endeavor.
The Opening Ceremony & Keynote Forum took place on morning of June 17th. Dr. Laszlo Takacs, Professor, University of Debrecen, Hungary; CEO/CSO Biosystems Immunolab Zrt, Hungary; Dr. Alexey Rak, Head of Bio Structure and Biophysics, Integrated Drug Discovery, Sanofi R&D, France; Dr. Kari Stefansson, Founder and CEO, deCODE genetics, Inc., Iceland; Dr. Stefan Platz, Senior Vice President, AstraZeneca, UK; Dr. Tim Hirst, Chairman & CEO, GPN Vaccines Ltd, Australia; Dr. Mary Pat Moyer, Founder, CEO and Chief Science Officer, INCELL Corporation LLC, USA gave brilliant plenary speeches. Dr. Tim Hirst as moderator of the Opening Ceremony and Keynote Forum expressed great gratitude to the presence of all delegates, speakers and participants and particularly wished all the guests a memorable stay in Budapest on behalf of the organizing committee.
As with previous editions, the cluster meeting is known for uplifting the future of the research fields by encouraging scientists and fellow researchers to present their work through oral speeches and poster presentation. Conference organizers took the privilege of felicitating keynote speakers, chairs and co-chairs whose support made conference a great success and also thank all other attendees who contributed a lot for the smooth functioning of the IDDST event.
Before, during and after the conference, we received warm support and valuable suggestions from the delegates on how to better plan and organize the next conference. Depending on the warmly support and good suggestions, we are confident in organizing IDDST-2025 in Sweden which would be better. We are looking forward to your continuing support and participation in our meeting next June in Stockholm, Sweden.
The Annual Congress of International Drug Discovery Science & Technology (IDDST), initiated from 2003, has been successfully organized in Shanghai (China), Beijing (China), Shenzhen (China), Nanjing (China), Haikou (China), Suzhou (China), Xi’an (China), Gyeonggi (South Korea), Osaka (Japan), Boston (USA), Kyoto (Japan), Tokyo (Japan) and Amsterdam (the Netherlands) and has attracted more than 10000 participants from over 50 countries and regions in the previous 19 years. The 20th IDDST (Europe) will be held during June 17-19, 2024 at Budapest, Hungary. It continues to expand with magnificent scientific and social programs to maximize your network in a free communication meeting environment.
● Learn Global Market Trends for Drug Discovery
● Organize up to 150+ Oral Presentations on the Latest Trend
● 200+ Attendees to Exchange Ideas and Build New Networks
● Bring together 20+ Exhibitors and Posters on New Development
● Opportunities to Visit the local Natural and Cultural Landscapes
|
Dr. Laszlo Takacs, Professor, University of Debrecen; CEO/CSO Biosystems Immunolab Zrt, Hungary; Foreign Member of the Hungarian Academy of Sciences |
|
Dr. Alexey Rak, Head of Bio Structure and Biophysics, Sanofi R & D, France |
|
Dr. Stefan Platz, SVP & Global Head Clinical Pharmacology & Safety Sciences, AstraZeneca, UK |
|
Dr. Kari Stefansson, Founder and CEO, deCODE genetics, Inc., Iceland |
|
Dr. Mary Pat Moyer, Founder, CEO and Chief Science Officer, INCELL Corporation LLC, USA; Fellow, National Academy of Engineering |
|
Dr. Tim Hirst, Chairman & CEO, GPN Vaccines Ltd, Australia |
 |
Dr. Sandor Szabo, Founding Dean & Professor, School of Medicine, American University of Health Sciences, USA |
 |
Dr. Nanduri R. Prabhakar, Harold Hines Jr. Professor of Medicine, University of Chicago, USA |
 |
Dr. Virginia Savova, Senior Director, Global Head of Single-cell Biology, Sanofi, USA |
 |
Dr. Gilbert Glady, President, EBMA Europe, France |
 |
Dr. Matthias Birkhoff, Vice President, Aptar Pharma, USA |
 |
Dr. Robert Lowery, President & CEO, BellBrook Labs, USA |
 |
Dr. Mark S McAlister, Director of Biophysics, AstraZeneca, UK |
 |
Dr. Adel K El-Naggar, Professor, The University of Texas, MD Anderson Cancer Center, USA |
 |
Dr. Dennis Paul, Professor, LSU Health Sciences Center New Orleans, USA |
 |
Dr. Robert F. Halliwell, Professor, School of Pharmacy, University of the Pacific, USA |
 |
Dr. Faz Chowdhury, CEO and Chairman, Nemaura Pharma Limited, UK |
 |
Dr. Philippe Lechat, Pharmacology Emeritus Professor, Paris city University, France |
 |
Dr. James Wai Kuo Shih, Senior Advisor, Xiamen Innovax Biotech Co., Ltd., China |
 |
Dr. Florian Montel, Head of Open Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
 |
Dr. Ruolan Han, Vice President, Nonclinical and Translational Research, OncoNano Medicine, Inc., USA |
 |
Dr. Kathleen M Smith, Senior Principal Research Scientist, IMM Computation Biology, AbbVie, USA |
 |
Dr. Arpad Szallasi, Professor, Faculty of Medicine, Semmelweis University, Hungary |
 |
Dr. Eyal Talor, Chief Scientific Officer, CEL-SCI Corporation, USA |
 |
Mr. Sarath Chandar, Chief Scientific Officer, SPI Pharma, USA |
 |
Dr. Dongling Ma, Professor, INRS – EMT; Canada Research Chair (Tier 1) in Advanced Functional Nanocomposites, Canada |
 |
Dr. James Dodgson, Associate Principle Scientist, R&D Oncology, Biologics Engineering, AstraZeneca, UK |
 |
Dr. Karel Smetana, Professor, Charles University, Czech Republic |
 |
Dr. Roger Scherrers, Head of Analytical Service, Waters, Wyatt Technology, Germany |
 |
Dr. Lars Neumann, Director Discovery Solutions, Proteros Biostructures GmbH, Germany |
 |
Dr. France Carrier, Professor, University of Maryland, Baltimore, USA |
 |
Dr. Jing Li, Professor of Oncology, Wayne State University, USA |
 |
Dr. Ravi V. Durvasula, Chair, Division of Infectious Diseases, Mayo Clinic, USA |
 |
Dr. Markus Klapper, Senior Scientist, Max Planck Institute for Polymer Research, Germany |
 |
Dr. Charu Gautam, Hon Professor of Clinical Pharmacology, Gujarat University, India |
 |
Dr. Justus Gross, Head of Vascular Surgery, Rostock University Medical Center, Germany |
 |
Dr. Pal Pacher, Lab Head, NIAAA, National Institutes of Health, USA |
 |
Dr. Jae Moon Lee, President, FAScinate Therapeutics, USA |
 |
Dr. Misuzu Kurokawa-Seo, Professor, Kyoto Sangyo University, Japan |
 |
Dr. Madhumita Chatterjee, Group Leader, University Hospital Tubingen, Germany |
 |
Dr. Kenji Sasaki, Gastroenterologist, Midtown Medicare Clinic, Japan |
 |
Dr. Arun Uthayashankar, Director, Transplant Anesthesiology, Tufts University School of Medicine, USA |
 |
Dr. Leandro Castellano, Head of Department of Biochemistry and Biomedicine, University of Sussex, UK |
 |
Dr. Tamas Hegedus, Professor, Semmelweis University, Hungary |
 |
Dr. Rebeca Ruiz, Principal Scientist, Pion Inc., UK |
 |
Dr. Jie Zheng, Professor and Department Chair, The University of Akron, USA |
 |
Dr. Nicolai Doliba, Research Associate Professor, University of Pennsylvania, USA |
 |
Dr. Sabrina Martucci Johnson, President and CEO, Dare Bioscience, USA |
 |
Dr. Andrzej Pilc, Professor, Institute of Pharmacology, Polish Academy of Sciences, Poland |
 |
Dr. Hubert Pellikaan, Owner, Nextstep Pharma BV; Co-Founder, DriPel BV, the Netherlands |
 |
Dr. Mahmood Moshiri, President and CEO, Next Pharma Inc., Canada |
 |
Dr. James A Stones, Patent Attorney, Beck Greener LLP, UK |
 |
Dr. Catherine Jewell, Patent and Trade Mark Attorney, Beck Greener LLP, UK |
 |
Dr. Sergey Suchkov, Professor in Immunology & Medicine, MGUPP, Russia |
 |
Mr. Thomas Ko, CTO, BioLingus GmbH, Switzerland |
 |
Dr. Robert T. Chatterton, Jr. Professor, Northwestern University, USA |
 |
Dr. Tomas Komprda, Professor, Mendel University in Brno, Czech Republic |
 |
Dr. Petr Maly, Head of Laboratory of Ligand Engineering, Institute of Biotechnology of Czech Academy of Sciences, Czech Republic |
 |
Dr. Pingsheng Hu, CEO, Sinorda Biomedicine, China |
 |
Dr. Mohamed Al-Ibrahim, Senior Physician Investigator, Pharmaron CPC; Adjunct Professor of Medicine, University of Maryland, School of Medicine, USA |
 |
Dr. Gitanjali Srivastava, Associate Professor, Vanderbilt University School of Medicine, USA |
 |
Dr. Pedro J. Caraballo, Associate Professor, Mayo Clinic College of Medicine and Science, USA |
 |
Dr. Ya Ha, Associate Professor of Pharmacology, Yale School of Medicine, USA |
 |
Dr. Wilfried Schupp, Senior Lecturer, Friedrich Alexander University, Germany |
 |
Dr. Csaba Hetenyi, Reader/Associate Professor, Medical School, University of Pecs, Hungary |
 |
Dr. Hanzhou Feng, Associate Principal Scientist, Merck & Co., Inc., USA |
 |
Ms. Jenny Lin, COO, CMIC, Inc., USA |
 |
Dr. Gerhard M. Kostner, Professor, Medical University of Graz, Austria |
 |
Dr. Chrisostomos Prodromou, Senior Lecturer, University of Sussex, UK |
 |
Dr. Fujian Song, Professor, Faculty of Medicine & Health Science, University of East Anglia, UK |
 |
Dr. Devinder K Dhawan, Professor, Department of Biophysics, Panjab University, India |
 |
Dr. Gary Edward Wild, Professor, Division of Gastroenterology, McGill University Health Centre, Canada |
 |
Dr. Ramona Pap, Senior Lecturer, Faculty of Pharmacy, University of Pecs, Hungary |
 |
Dr. Tony B. D’Assoro, Associate Professor of Pharmacology, Mayo Clinic Cancer Center, USA |
 |
Dr. Jingchun Fan, Associate Professor, Gansu University of Chinese Medicine, China |
Dr. Laszlo Takacs,
Professor, University of Debrecen; CEO/CSO Biosystems Immunolab Zrt, Hungary
Dr. Arpad Szallasi,
Professor, Faculty of Medicine, Semmelweis University, Hungary
Budapest Convention Bureau
TargetEx Ltd, Hungary
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
© 2003-2024 All rights reserved by BITeomics |